Biotech Values

[DewDiligence]

GRAIL starts clinical trial to test liquid-biopsy diagnostic for early-stage cancer in randomly enrolled subjects:

https://www.businesswire.com/news/home/20200218005577/en

GRAIL, Inc., a healthcare company whose mission is to detect cancer early, when it can be cured, today announced the initiation of the PATHFINDER Study. A prospective, multi-center study, PATHFINDER marks the first time GRAIL’s test results will be returned to healthcare providers and communicated to participants to help guide appropriate diagnostic workup for more than 50 cancer types.

Initial PATHFINDER health system partners include Dana-Farber Cancer Institute, Intermountain Healthcare, Mayo Clinic, Oregon Health & Science University, and Sutter Health with plans to expand to additional partners. The first participants have been successfully enrolled.

GRAIL aims to enroll 6,200 participants who will be followed at least 12 months. (Note that I didn’t say, “6,200 patients.”)